B+
Bull case
20%
Probability
Target price
$19.00
Analysis reference price unavailable
Analysis 2026-05-28 · RankAlpha Sentiment Codex
VTRS
ViatrisCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The Q1 print and guidance reaffirmation suggest Viatris can still deliver operating leverage, while Greater China and branded-drug strength provide near-term support. The meloxicam NDA adds a discrete pipeline readout that could widen the valuation range if it clears FDA review.
Posture
Mixed
Lead driver
Sentiment
What changed
4 setup hits (3d) with net bullish as of 2026-09-09.
What can break
Fast-acting meloxicam is still a binary FDA review until the Dec. 27, 2026 PDUFA date.
Momentum
38
Value
67
Sentiment
57
Setup hits (3d)
4 · Net Bullish
AI TargetsBase $15.80 · Bull $19.00 · Bear $12.50Analysis 2026-05-28; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-28 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Bullish
Target $18.88
Why
Momentum38 · Δ7d +17.6
Value67 · Δ7d 0.0
Sentiment57 · Δ7d +5.7
So what
Balanced signals (Net Bullish). Wait for confirmation before sizing up.
Confirming evidence
- • 4 setup hits (3d) with net bullish as of 2026-09-09.
- • Sentiment remains the lead driver in the composite, 7D delta +5.7.
Contradictions & invalidation
- • Fast-acting meloxicam is still a binary FDA review until the Dec. 27, 2026 PDUFA date.
- • The May 2026 CFO transition adds a small but real near-term execution/continuity risk.
- • Management held guidance rather than raising it, the packet’s median target is below the 16.29 anchor, and core generics/margin pressure can still offset launch wins.
Catalyst clock
2026-05-07
Q1 2026 beat and guidance reaffirmation
Lead driver: Sentiment · See AI snapshot
Momentum
38
9% active weight
Current posture
7d trendImproving
Δ7d
+17.6
Δ21d
-18.8
Value
67
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.5
Sentiment
57
62% active weight
Current posture
7d trendImproving
Δ7d
+5.7
Δ21d
-1.2
Why this grade
Composite grade C. Momentum 38.1 / Value 66.8 / Sentiment 56.9
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-28. Scenario method
Most likely
B
Base case
55%
Probability
Target price
$15.80
Analysis reference price unavailable
Analysis 2026-05-28 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$12.50
Analysis reference price unavailable
Analysis 2026-05-28 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$18.64B
Beta
0.78
Shares Out
1.15B
P/E (TTM) · Derived
-5.4
P/S (TTM)
1.01
P/FCF (TTM)
13.63
Rev YoY
+5.0%
EPS YoY
+2517.9%
Gross Margin
+39.6%
Op Margin
+9.7%
Net Debt
$13.25B
Current Ratio
1.49
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data